SeraCare Life Sciences Inc. of Milford says it is considering “strategic alternatives” including a possible sale of the company.
In June, SeraCare shareholder MSMB Capital Management made an unsolicited offer to buy all outstanding shares of the company for $82 million, or $4.25 per share. SeraCare said at the time that it would review the proposal.
Financial advisory firm Lazard Ltd. is helping the company’s board of directors evaluate possible actions. SeraCare said it will not provide updates or comment on possible actions unless the board recommends a specific course of action.
